About this trial
The primary objective of this pilot randomized controlled trial (RCT) is to test the feasibility (consent rate, retention rate, participant burden, adherence, technical issues, safety) and usability (system usability scale, SUS) of Omnidirectional treadmill Virtual Reality training (omni-VR) among chronic stroke survivors. Our secondary objective is to (1) estimate the extent to which cognition, brain activation during a dual task activity, walking ability, and dynamic balance change after 3 months of training among intervention participants (omni-VR) and traditional exercise controls, and (2) estimate the extent to which health-related quality of life and motivation co-evolve with our secondary outcomes.
Researchers will compare the intervention group and control group to evaluate the impact of omni-VR on cognition and physical function among stroke survivors.
Participants will:
* undergo a 45-minute training session 3 times per week for 12 weeks * intervention group: omni-VR * control group: traditional exercise program (strengthening and walking activities)
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18
Stroke ≥ 6 months ago (confirmed with chart review)
Living within 50 km of Halifax, Nova Scotia
Functional Ambulation Category of 3 or greater on a scale of 0-5, to ensure the participant is able to walk with supervision or independently. This criterion was selected to ensure participants could safely participate in the intervention.
Disqualifiers
Unstable serious medical condition
Resting blood pressure >180/100mmHg
History of abnormal untreated heart rhythm
Pregnancy
Trial design
Parallel
Treatments tested in this trial
Omnidirectional Virtual Reality and Treadmill Training
DeviceOmni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.
Traditional Exercise
BehavioralA traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.
Treatment groups
Trial outcomes
Primary outcomes
Consent rate
Consent rate is the percentage of eligible individuals who participate. The investigators expect a consent rate of at least 40%.
Retention rate
Retention rate is the percentage of participants who complete the 12-week intervention. The investigators expect a retention rate of 80% for the intervention group.
Usability of the Omnidirectional Treadmill and Virtual Reality Game
Usability will be assessed by System Usability Scale (SUS) out of 100 points. The investigators expect a SUS score of 71 or higher among all participants.
Participant burden
Participant burden will be measured by the percentage of participants finishing assessments in 100 minutes or less. The investigators anticipate at least 85% of participants completing assessments within the time limit.
Secondary outcomes
Cognitive function
The investigators will use the Computerized MoCA \[Montreal Cognitive Assessment\] Duo to evaluate participants' cognitive function.
Executive Function
The investigators will use the Dimensional Change Card Sort to evaluate participants' executive function.
Working memory
The investigators will use the List Sorting Working Memory Test to evaluate participants' working memory.
Brain activation in prefrontal and premotor cortices
Brain activation using fNIRS \[Functional near-infrared spectroscopy\] in the prefrontal and premotor regions of interest during a single task (steady-state omnidirectional treadmill walking) and two cognitive-physical dual-task activities (simple dual-task: steady-state omnidirectional treadmill walking while repeating the same word and complex dual-task: steady-state omnidirectional treadmill walking while performing a verbal fluency test)
Other outcomes
Motivation of participant
The investigators will measure motivation by intrinsic motivation inventory. Higher scores indicate better results.
Health-related quality of life of participant
The investigators will measure health-related quality of life by the Stroke Impact Scale-3.0. Higher scores indicate better results.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Nova Scotia Health Authority
Lead sponsor
Dalhousie University
Sponsor institution
Brain Canada
Collaborator